Antiphospholipid Syndrome

Unexplained chorea, especially among women, should prompt testing for antibodies associated with antiphospholipid syndrome, according to data published in Lupus Science & Medicine.

SAN DIEGO — Preventing the first thrombosis, and better circumvention of the second, are currently the biggest obstacles in managing antiphospholipid syndrome, according to a speaker at the 2024 Congress of Clinical Rheumatology West.

Patients with prior sinusitis demonstrate an increased risk for many rheumatic diseases, including antiphospholipid syndrome, Sjögren’s disease and seronegative rheumatoid arthritis, according to data published in RMD Open.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

Updated classification criteria for antiphospholipid syndrome require patients display at least one positive antiphospholipid antibody test within 3 years of a linked disease manifestation, according to new guidance from the ACR and EULAR.

The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone equivalent or less, according to the updated 2023 EULAR recommendations for the management of systemic lupus erythematosus.

SAN DIEGO — Pregnant patients with concomitant systemic lupus erythematosus and antiphospholipid syndrome have an 18-fold increased risk for cardiovascular events vs. healthy pregnant controls, said a speaker at ACR Convergence 2023.

Upcoming American College of Rheumatology and EULAR joint classification criteria for antiphospholipid syndrome will “create a homogenous patient population” to increase research, according to a presenter at the 2023 AWIR annual conference.

Pregnancies among patients with Sjögren’s syndrome demonstrate “very good prognoses” for both the parent and fetus, and do not reflect an increased risk for adverse outcomes, according to data published in The Lancet Rheumatology.

Anticardiolipin IgA and a2GPI IgA positivity, together at a single time point, indicate an increased risk for future atherosclerotic cardiovascular disease events, according to data published in JAMA Network Open.